{"filings":[{"id":1471678,"accession_number":"0001193125-26-296190","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2026-07-06T20:11:47+00:00","items":["5.02"],"status":"ready","headline":"Kalaris Therapeutics announces director resignation and election of Laurie Keating","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Morana Jovan-Embiricos resigned from board and audit committee effective July 3, 2026; no disagreement with company.","Laurie Keating elected as Class I director effective August 1, 2026, and appointed to audit committee.","Keating receives option for 18,000 shares vesting over 3 years, annual cash $40,000 board plus $7,500 audit committee.","Keating will enter standard indemnification agreement; compensation per non-employee director policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860918,"accession_number":"0001193125-26-257388","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2026-06-04T20:06:56+00:00","items":["5.07"],"status":"ready","headline":"Kalaris Therapeutics holds 2026 annual meeting; all proposals pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Napoleone Ferrara, David Hallal, Leone Patterson as Class III directors (three-year terms).","Advisory vote on executive compensation approved: 15.85M for, 0.50M against.","Shareholders recommended say-on-pay every year; board adopts annual frequency.","Ratified Deloitte & Touche as auditor for FY 2026: 19.77M for, 1.58K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22761,"accession_number":"0001193125-26-218240","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2026-05-12T12:08:34+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.9M in Q1 2026 vs $10.2M in Q1 2025; R&D expense $7.6M (+27% YoY).","Cash and securities $104.9M at March 31, 2026, down from $118.0M at December 31, 2025; runway into Q4 2027.","Patient screening underway in Phase 1b/2 multiple-ascending-dose trial of TH103 for wet AMD; data expected 1H 2027.","New manufacturing batch completed with process enhancements reducing impurities; Phase 3 initiation on track for end of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95201,"accession_number":"0001193125-26-151215","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Matthew Gall resigns; CAO Brett Hagen takes over as principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Gall resigned as CFO, effective April 14, 2026.","Brett Hagen, Chief Accounting Officer since Jan 2019, will serve as principal financial officer.","Hagen previously held finance roles at Eloxx Pharmaceuticals, Proteostasis Therapeutics, and BIND Therapeutics.","No changes to Hagen’s compensatory plans or arrangements were disclosed.","Resignation reason not stated; departure is effective April 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108083,"accession_number":"0001193125-26-109437","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kalaris reports positive Phase 1a TH103 data, $118M cash, net loss $43.4M in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1a in nAMD showed mean 10-letter BCVA gain, 129µm CST improvement, ~95% intraretinal fluid reduction.","TH103 plasma Cmax 27-51 fold lower than approved anti-VEGF agents; no DLTs or serious AEs observed.","Cash, equivalents and marketable securities $118.0M as of Dec 31, 2025; funding into Q4 2027.","Net loss $43.4M for 2025 vs $69.2M in 2024; R&D expense $30.8M, G&A $15.4M.","Completed $50.0M oversubscribed private placement in Dec 2025; Phase 1b/2 preliminary data expected 1H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108082,"accession_number":"0001193125-26-097548","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kalaris releases corporate presentation with TH103 trial updates but no specific figures disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation includes timelines for reporting Phase 1b/2 data of TH103 and plans to initiate Phase 3; no dates or numbers given in filing.","Cash runway guidance mentioned in the presentation; precise amount or duration not provided in the 8-K.","Presentation to be used at Leerink Partners Global Healthcare Conference and other investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124502,"accession_number":"0001193125-25-323706","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Kalaris Therapeutics raises $50M in oversubscribed private placement; cash runway into Q3 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$50M gross via 4.2M shares at $10.00/share and 800K pre-funded warrants at $9.9999.","Pricing was at a premium to prior 5-day closing price on Nasdaq.","Investors include ADAR1 Capital, Coastlands, Invus, RTW, Samsara BioCapital, Woodline Partners.","Proceeds to advance TH103 for neovascular AMD and for working capital; cash runway to Q3 2027.","Private placement expected to close Dec 19, 2025; registration rights to file after April 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124501,"accession_number":"0001193125-25-322950","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kalaris Therapeutics reports positive Phase 1a data for TH103 in nAMD; accelerates development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean 10-letter BCVA gain and 129 µm CST improvement at Month 1 across all dose levels (0.5–2.5 mg).","Mean ~95% reduction in central subfield intraretinal fluid; no dose-limiting toxicities or TH103-related serious AEs.","Two transient IOI cases at 2.5 mg resolved with manufacturing process change; zero new IOI in 6 subsequent subjects.","31% of patients (4/13) required no additional anti-VEGF treatment during the 6-month follow-up after a single injection.","Plasma Cmax 27–51-fold lower vs. leading anti-VEGF agents; Phase 1b/2 enrollment ongoing, preliminary data expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124500,"accession_number":"0001193125-25-276060","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kalaris Q3 net loss narrows to $11.9M; cash $77M; Phase 1a data on track for year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1a SAD trial initial clinical data (safety, efficacy, PK) expected by year end 2025.","Phase 1b/2 MAD trial in nAMD enrolling up to 80 patients; initial data expected 2H 2026.","Cash, cash equivalents and ST investments $77.0M as of Sept 30, 2025; expected to fund operations into 2027.","R&D expense $9.1M (vs $36.0M in Q3 2024); net loss $11.9M (vs $38.1M).","Selected KBI Biopharma as CDMO; hired CFO Matthew Gall; opened NJ headquarters."],"consensus_eps_estimate":-0.6659,"consensus_eps_actual":-2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124499,"accession_number":"0001193125-25-261697","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kalaris Therapeutics appoints Matthew Gall as CFO effective November 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Gall appointed CFO and Treasurer effective Nov 3, 2025; succeeds Brett Hagan as principal financial officer.","Annual base salary of $485,000; eligible for target bonus of up to 40% of base salary.","Received incentive stock option for 235,000 shares vesting over 4 years at closing price on grant date.","Severance: 9 months salary (12 months if within 12 months of change in control) plus COBRA and accelerated equity.","Gall previously CFO of iTeos Therapeutics (June 2020 – Aug 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141175,"accession_number":"0001193125-25-179466","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kalaris Therapeutics stockholders elect two Class II directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Srinivas Akkaraju and Andrew Oxtoby elected as Class II directors for three-year terms expiring 2028.","Akkaraju: 14,626,646 for, 144,695 withheld; Oxtoby: 14,668,424 for, 102,917 withheld.","Ratification of Deloitte & Touche as independent auditor for FY2025 approved with 16,090,928 for, 6,975 against, 1,786 abstain.","Broker non-votes of 1,328,348 on director elections due to routine matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141174,"accession_number":"0001193125-25-179464","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kalaris Q2 2025 net loss $11.4M; Phase 1 TH103 data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.4M ($0.61/shr) vs $5.7M ($4.26/shr) in Q2 2024; no revenue in either period.","Cash $88.4M at June 30, 2025 (up from $1.6M at Dec 31, 2024) after AlloVir merger.","R&D expenses $8.4M (up from $3.2M YoY) driven by Phase 1 clinical trial initiation.","Enrolling nAMD patients in Phase 1 trial of anti-VEGF TH103; initial data expected Q4 2025.","Hired Kristine Curtiss as SVP of Clinical; over 25 years ophthalmology experience."],"consensus_eps_estimate":-0.5304,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158975,"accession_number":"0001193125-25-143202","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Kalaris sets Aug 12, 2025 annual meeting; stockholder proposals due June 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 annual meeting scheduled for August 12, 2025; postponed from typical anniversary date.","Rule 14a-8 stockholder proposals must be received by June 30, 2025 to be included in proxy materials.","Director nominations under by-laws also due June 30, 2025, as meeting delayed over 60 days from prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158974,"accession_number":"0001193125-25-119408","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kalaris Q1 net loss $10.2M ($2.52/shr); cash $101M; TH103 Phase 1 data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.2M for Q1 2025 vs $3.4M for Q1 2024; diluted EPS loss $2.52.","Cash and equivalents $101.0M as of March 31, 2025, expected to fund operations into Q4 2026.","R&D expenses $6.0M (up from $2.0M YoY) driven by TH103 Phase 1 trial initiation.","Phase 1 trial of TH103 for nAMD actively enrolling; initial clinical data expected Q4 2025.","Completed merger with AlloVir in March 2025; appointed Leone Patterson to Board and Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158973,"accession_number":"0001193125-25-082819","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kalaris Therapeutics enters new CEO employment agreement with severance benefits; CAO severance set","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Oxtoby's new base salary is $569,100; target bonus up to 55% of base salary.","On non-CIC termination without cause/good reason: 12 months base salary plus COBRA.","On CIC termination: 18 months base salary, 150% target bonus lump sum, 18 months COBRA, full equity acceleration.","CAO Hagen gets 9 months base salary (non-CIC) or 12 months plus 100% target bonus lump sum (CIC) and equity acceleration.","Both agreements require release and continued compliance with restrictive covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158972,"accession_number":"0001193125-25-072869","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kalaris Therapeutics appoints Leone Patterson to Board as Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leone Patterson elected Class III director effective April 3, 2025; term expires at 2026 annual meeting.","Patterson named Chair of Audit Committee; committee now includes Patterson, Adamis, and Jovan-Embiricos.","No arrangements or family relationships with other directors; standard indemnification agreement to be entered.","Company expects to adopt new non-employee director compensation program; Patterson will receive compensation once adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177412,"accession_number":"0001193125-25-056725","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.01","9.01","5.02","2.02","5.01","5.03","5.06","7.01"],"status":"ready","headline":"AlloVir completes reverse merger with Legacy Kalaris; ticker changes to KLRS on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Post-merger combined company focuses on retinal disease therapeutics; TH103 is lead candidate.","Legacy Kalaris securityholders own 74.47% of combined company; ~18.7M shares outstanding.","Samsara BioCapital LP holds 61.19% of shares post-merger; new board and officers appointed.","Ticker changes from ALVR to KLRS on Nasdaq Global Market effective March 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177411,"accession_number":"0001193125-25-052940","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"AlloVir shareholders approve merger with Kalaris; combined co to trade as KLRS","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders voted to approve merger: 3,543,715 for, 368,843 against, 282 abstain out of 3,912,840 votes cast.","2020 Plan amended: share reserve increased by 5% of post-merger outstanding; plan term extended to 10th anniversary of closing.","Combined company to be renamed Kalaris Therapeutics, trading on Nasdaq under ticker KLRS after closing.","Kalaris lead candidate TH103 (anti-VEGF fusion protein) in Phase 1 trial for neovascular AMD; plans for DME and RVO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177410,"accession_number":"0001193125-25-007077","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"AlloVir effects 1-for-23 reverse stock split effective Jan 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-23 ratio, approved by board on Jan 9 after stockholder vote.","Effective 4:05 pm ET Jan 15; trading on split-adjusted basis Jan 16 under ALVR.","No fractional shares; cash in lieu based on Jan 15 closing price.","Reverse split is part of preparations for proposed merger with Kalaris Therapeutics.","New CUSIP number 019818202; par value and authorized shares unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177409,"accession_number":"0001193125-25-004527","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AlloVir announces 1-for-23 reverse stock split effective Jan 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-23 reverse stock split; effective 4:05 PM ET Jan 15, 2025.","Stock to trade on split-adjusted basis on Nasdaq from Jan 16, 2025; CUSIP 019818202.","No fractional shares; cash payment in lieu at closing price on Jan 15.","Reverse split authorized by stockholders at special meeting on Jan 9, 2025 in connection with proposed merger with Kalaris Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177408,"accession_number":"0001193125-25-004091","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AlloVir shareholders approve reverse stock split ratio range 1:15–1:35; board to set exact ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["96,216,120 votes for, 12,082,172 against, 303,036 abstain; adjournment not needed.","Reverse split ratio of any whole number between 1:15 and 1:35, effective before Jan 10, 2026.","Board will determine exact ratio and timing without further shareholder approval.","Split is in connection with proposed merger with Kalaris Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194152,"accession_number":"0001193125-24-283140","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Diana Brainard departs; President/CFO Vikas Sinha named CEO effective Dec 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diana Brainard resigned as CEO and director effective Dec 19; no disagreement with company on operations, policies, or practices.","Vikas Sinha (President, CFO since 2019) appointed CEO and principal executive officer same day; he has over 20 years life sciences finance experience.","Brainard receives $1.88M lump sum (36-mo salary), $376k target bonus, $100k merger completion bonus, and acceleration of 371,525 RSUs.","Company previously disclosed proposed merger with Kalaris Therapeutics, Inc.; Sinha served as CFO of Alexion Pharma (ALXN) previously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194151,"accession_number":"0001193125-24-253747","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AlloVir to merge with Kalaris in all-stock deal; Kalaris stockholders to own ~75% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["AlloVir acquires Kalaris; pre-merger AlloVir stockholders own ~25.05%, Kalaris ~74.95% on fully diluted basis, subject to net cash adjustments.","Combined company expected to have ~$100M cash at close (expected Q1 2025), providing runway into Q4 2026.","Pipeline focuses on TH103 (anti-VEGF fusion protein) for neovascular AMD; Phase 1 data expected Q3 2025; also planned for DME and RVO.","Stockholders owning 87.4% of Kalaris and 29.4% of AlloVir have entered support agreements to vote in favor.","Post-close company to rename Kalaris Therapeutics, trade on Nasdaq under ticker KLRS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210476,"accession_number":"0001193125-24-174335","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"AlloVir terminates Waltham lease, pays $7M early termination fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated lease with BP Bay Colony for 78,541 sq ft at 1100 Winter Street, Waltham, effective June 30, 2024.","Paid $7M early termination payment due 5 business days after July 1, 2024; no further rent obligations.","Lease originally scheduled to expire July 31, 2030; Phase II premises (59,305 sq ft) never occupied.","Surrendered Phase I premises (19,236 sq ft) in condition required by lease; Phase II surrendered early.","Termination reflects downsizing; company paid $7M to exit long-term lease commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228798,"accession_number":"0001193125-24-159226","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"AlloVir terminates Waltham sublease, agrees to pay $5.7M termination fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease terminated effective June 30, 2024; originally set to expire July 31, 2028.","AlloVir will pay $5.7 million termination fee to AMAG Pharmaceuticals.","AlloVir released from future rent obligations; no restoration beyond broom-clean required.","Security deposit of $297,717 to be returned per sublease terms.","Landlord BP Bay Colony LLC consented to termination on June 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228797,"accession_number":"0001193125-24-157311","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AlloVir stockholders elect three Class I directors and ratify Deloitte as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Juan Vera (77.7M for, 4.2M withhold), Morana Jovan-Embiricos (76.2M for, 5.8M withhold), Derek Adams (76.2M for, 5.7M withhold) as Class I directors.","Ratified Deloitte & Touche as independent auditor for FY2024: 104.2M for, 276K against, 400K abstain.","Broker non-votes totaled 22,994,115 on each director election; no other matters voted on.","Meeting held June 6, 2024; record date April 15, 2024 with 114,912,515 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228796,"accession_number":"0001193125-24-153013","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AlloVir approves $100K transaction bonuses for CEO, CFO, GC contingent on 2024 change of control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved $100K cash bonuses to CEO Diana Brainard, President/CFO Vikas Sinha, and GC Edward Miller.","Bonuses contingent on Board execution of a definitive change of control agreement in fiscal 2024 and continued employment through closing.","Payments are termed Transaction Bonuses; Brainard and Sinha abstained from voting on their own bonuses.","The bonuses signal active pursuit of a strategic transaction, likely a sale or merger of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247447,"accession_number":"0001193125-24-032160","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"AlloVir receives Nasdaq notice of non-compliance; bid price below $1.00 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Feb 9, 2024, for bid price < $1.00 over 30 consecutive business days.","Has 180 days (until Aug 7, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may get additional 180 days if certain criteria are met.","Evaluating options including reverse stock split to regain compliance.","Common stock continues trading on Nasdaq Global Select under symbol ALVR for now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247446,"accession_number":"0001193125-24-002563","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"AlloVir reduces workforce by ~95%; expects $13M in severance charges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved cutting ~95% of employees to preserve capital after discontinuing three global Phase 3 posoleucel studies (announced Dec 22, 2023).","Reduction primarily in Q1 2024, substantially complete by April 15, 2024.","Expects ~$13M in personnel-related restructuring charges (severance and benefits) largely incurred in Q1 2024.","Additional charges may arise from retention efforts or other events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264895,"accession_number":"0001193125-23-301777","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AlloVir discontinues all three Phase 3 posoleucel trials after DSMB futility analyses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Phase 3 trials for prevention, hemorrhagic cystitis, and adenovirus stopped after separate DSMBs deemed each unlikely to meet primary endpoints.","No safety concerns observed; discontinuation based on pre-planned futility analyses.","Company to prioritize capital preservation; held $213.3M cash and equivalents as of Sep 30, 2023.","AlloVir will review strategic alternatives including merger, sale, or licensing of assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264894,"accession_number":"0001193125-23-268875","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AlloVir Q3 net loss $44.3M ($0.39/sh); cash $213.3M funds trials to H2 2024 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.3M vs $42.1M in Q3 2022; diluted EPS loss $0.39 vs $0.50.","Cash, equivalents and short-term investments $213.3M at Sep 30, down from $233.8M at Dec 31, 2022.","R&D expense $34.2M, up from $30.0M YoY, driven by posoleucel trial costs.","Three Phase 3 posoleucel trials enrolling; topline data expected in H2 2024 for all three.","FY 2023 operating expense guidance $150M-$170M, excluding non-cash items."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282089,"accession_number":"0001193125-23-202285","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AlloVir Q2 net loss $45.3M; cash $246.5M; three Phase 3 trials on track for H2 2024 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $45.3M ($0.48 per share) vs $44.6M ($0.69) in Q2 2022.","Cash, equivalents, and short-term investments $246.5M as of June 30, 2023.","Closed public offering with gross proceeds ~$75M, extending cash runway into 2025.","Three Phase 3 registrational trials of posoleucel in allo-HCT patients; data expected H2 2024.","FY 2023 operating expense guidance $150M-$170M excluding non-cash items."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301180,"accession_number":"0001193125-23-175095","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"AlloVir prices public offering of 20M shares at $3.75/share for $75M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 20,000,000 shares at $3.75 per share; gross proceeds of $75.0M.","Net proceeds estimated at $70.2M ($80.7M if underwriters fully exercise 30-day option for 3M additional shares).","Offering expected to close on or about June 26, 2023; underwriters include J.P. Morgan, Morgan Stanley, and BofA.","Shares offered under existing shelf registration; 90-day lock-up for AlloVir executives and directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301179,"accession_number":"0001193125-23-171157","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AlloVir suspends ATM equity program; terminates prospectus supplement with SVB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notified SVB Securities on June 21, 2023 to suspend and terminate the ATM prospectus supplement.","No sales of common stock will be made under the Sales Agreement until a new prospectus supplement or registration statement is filed.","Sales Agreement dated August 6, 2021 remains in full force and effect except for the terminated supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301178,"accession_number":"0001193125-23-146091","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"AlloVir stockholder vote approves doubling authorized common shares to 300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment filed May 15 increases authorized common from 150M to 300M shares.","Proposal 3 approved: 86,571,410 for, 544,049 against, 1,225 abstain.","Class III directors elected: Bornstein, Brainard, Hallal, Tomasello; vote totals provided.","Ratification of Deloitte & Touche as auditor for FY2023 approved: 86,411,460 for.","Record date March 15, 2023; 93,511,558 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301177,"accession_number":"0001193125-23-135024","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AlloVir reports Q1 net loss $41.2M; Phase 3 posoleucel trials on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.2M ($0.44/share) vs $43.9M ($0.69/share) in Q1 2022.","Cash, cash equivalents and short-term investments were $202.6M as of March 31, 2023.","R&D expenses $30.7M, G&A $12.5M; FY 2023 operating expense guidance $150M-$170M excl. non-cash.","Three Phase 3 registrational trials of posoleucel in allo-HCT patients continue enrolling; data readouts expected in 2024.","Positive Phase 2 data for posoleucel in BK viremia in kidney transplant recipients to be presented at ATC 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321061,"accession_number":"0001193125-23-046651","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AlloVir appoints Derek Adams to board; Ansbert Gadicke retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Derek Adams, Ph.D. appointed to Board effective March 1, 2023, filling vacancy from Ansbert Gadicke's retirement.","Dr. Adams brings over 20 years of experience in manufacturing biologic and gene therapies; currently CEO of Stellular Bio.","Ansbert Gadicke, M.D. retires from board effective February 28, 2023; no disagreement with company.","AlloVir is a late-clinical stage allogeneic T cell immunotherapy company with three ongoing Phase 3 studies for posoleucel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321060,"accession_number":"0001193125-23-039772","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AlloVir reports FY2022 net loss of $168.7M and positive Phase 2 posoleucel data in kidney transplant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 net loss $168.7M ($2.20/share); R&D spend $118.9M; cash & securities $233.8M as of Dec 31, 2022.","2023 operating expense guidance of $150-170M (excl. non-cash); Phase 3 enrollment completion expected by end of 2023 with 2024 data.","Phase 2 study: posoleucel achieved ≥1-log viral load reduction in 39% vs 14% placebo; biweekly dosing 50%.","In high viral load (≥10,000 copies/mL): 69% posoleucel vs 25% placebo achieved ≥1-log reduction; 75% for biweekly dosing.","Posoleucel well tolerated with balanced safety; no GVHD, cytokine release syndrome, or treatment-related acute rejection."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321059,"accession_number":"0001193125-23-004128","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AlloVir plans Phase 3 posoleucel enrollment completion in 2023; $234M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash balance $234M as of Dec 31, 2022; FY 2023 operating expenses guided $150M-$170M.","Enrollment completion for all three posoleucel Phase 3 trials expected by end of 2023; data readouts in 2024.","Topline results from Phase 2 BKV treatment study in kidney transplant patients expected in Q1 2023.","Final Phase 2 multi-virus prevention data presented at ASH 2022 showed substantially lower infection rates.","CEO Diana Brainard to present at J.P. Morgan Healthcare Conference on Jan 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339159,"accession_number":"0001193125-22-289920","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AlloVir announces resignation of Chief Commercial Officer Jeroen van Beek effective Nov 23","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["EVP and CCO Jeroen van Beek resigns Nov 23, 2022 to pursue new opportunities; will consult through Dec 31.","Company begins search for new head of Commercial organization.","Separation benefits: lump sum base salary through Dec 31, 2022, 2022 cash bonus, COBRA through Nov 23, 2023, and accelerated vesting of options/RSUs vesting by Dec 31, 2022.","Separation Agreement includes non-competition, confidentiality, and non-solicitation covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339158,"accession_number":"0001193125-22-276390","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AlloVir reports Q3 net loss $42.1M; cash $264.1M, advancing Phase 3 posoleucel trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.1M ($0.50/sh) in Q3 2022 vs $45.5M ($0.72) in Q3 2021.","Cash & securities $264.1M; raised $126.4M net from registered direct offering July 2022.","R&D expenses $30.0M, G&A $12.9M; FY2022 opex guidance $130M-$145M excl. stock comp.","Phase 3 posoleucel trials ongoing; final Phase 2 multi-virus prevention data by year-end.","Topline Phase 2 BK viremia data in kidney transplant patients expected Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356535,"accession_number":"0001193125-22-211843","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AlloVir Q2 net loss $44.6M; $126.5M July offering extends cash runway for Phase 3 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.6M ($0.69/sh) vs $37.6M ($0.60/sh) in Q2 2021; R&D expense rose to $31.4M.","Cash $172.7M at June 30; July registered direct offering raised $126.5M to fund three Phase 3 posoleucel trials.","Phase 2 multi-virus prevention final data expected year-end; Phase 2 BKV treatment topline in Q1 2023.","Posoleucel granted EMA orphan designation for prevention; now holds three FDA RMAT designations.","FY2022 operating expense guidance $130-145M, excluding stock-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356534,"accession_number":"0001193125-22-202719","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["1.01","7.01"],"status":"ready","headline":"AlloVir raises $126.6M in registered direct offering at $4.61/share for Phase 3 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 27.46M shares at $4.61 each; gross proceeds ~$126.6M.","Funds to complete enrollment and data readouts in three ongoing Phase 3 trials of posoleucel.","New investors include Kite (Gilead), F2 Ventures, ElevateBio, Invus, Redmile, EcoR1 Capital, GMT Capital.","Offering expected to close July 28, 2022; no underwriter. Cash & equivalents $172.7M as of June 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374966,"accession_number":"0001193125-22-155023","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AlloVir stockholders elect Sinha and Brenner as Class II directors; ratify Deloitte","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Vikas Sinha elected with 47,229,880 for, 4,036,755 withhold, 10,745,678 broker non-votes.","Malcolm Brenner elected with 48,449,496 for, 2,817,139 withhold, 10,745,678 broker non-votes.","Ratification of Deloitte & Touche as auditor approved: 61,754,011 for, 250,317 against, 7,985 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374965,"accession_number":"0001193125-22-141341","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AlloVir Q1 net loss $43.9M; advances posoleucel to Phase 3 multi-virus prevention","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $43.9M ($0.69/share) vs $30.9M ($0.50) in Q1 2021; R&D spend $29.1M.","Cash, equivalents & marketable securities $201.4M, down from $248.1M at year-end 2021.","Initiated global Phase 3 registrational study of posoleucel to prevent 6 viruses in allo-HCT patients.","FDA granted third RMAT designation for posoleucel multi-virus prevention; estimated addressable population 40,000 patients/year.","FY2022 operating expense guidance reaffirmed at $130M–$145M excluding stock-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393381,"accession_number":"0001193125-22-090667","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AlloVir appoints Shawn Tomasello to board; co-founder John Wilson to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Tomasello appointed to Board of Directors effective March 29, 2022, serving as Class III director until 2023 annual meeting.","John Wilson, co-founder and former executive director, will retire and not stand for re-election at 2022 annual meeting.","Ms. Tomasello brings over 35 years of life sciences experience, with specific expertise in cell and gene therapy commercialization.","Board determined Ms. Tomasello is independent under Nasdaq listing standards; she will receive standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393380,"accession_number":"0001193125-22-033574","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AlloVir reports FY2021 net loss $172M; cash $248.1M; three Phase 3 trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $172.0M ($2.74/share) for 2021 vs. $69.8M in 2020; cash $248.1M at year-end.","Three Phase 3 registrational studies of posoleucel: HC, AdV treatment enrolling; multi-virus prevention expected 1H22.","R&D expenses $120.7M in 2021; 2022 operating expense guidance $130-145M (excl. stock comp).","ALVR106 Phase 1/2 for respiratory viruses initiated Dec 2021; ALVR107 preclinical for hepatitis B ongoing.","Initial data from posoleucel BK viremia POC study in kidney transplant expected 1H22."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393379,"accession_number":"0001193125-22-005069","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AlloVir reports $248.1M cash at year-end 2021; JPM presentation ongoing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited cash, equivalents and marketable securities total $248.1M as of Dec 31, 2021.","Corporate presentation furnished for J.P. Morgan Healthcare Conference on Jan 10, 2022.","AlloVir is a leader in allogeneic, off-the-shelf virus-specific T cell therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411892,"accession_number":"0001193125-21-359961","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2021-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AlloVir CMO Agustin Melian to depart at year-end; Richard Riese to lead clinical programs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Agustin Melian, MD, leaves AlloVir at end of 2021 after two and a half years.","Melian will serve in an advisory role for transition; CEO thanked him for advancing posoleucel into Phase 3.","Richard Riese, MD, PhD, SVP Clinical Research, will oversee clinical development including Phase 3 posoleucel studies.","Company's pipeline of virus-specific T cells continues; no change to clinical strategy disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411891,"accession_number":"0001193125-21-354690","cik":1754068,"company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","form_type":"8-K","filed_at":"2021-12-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AlloVir announces positive preliminary Phase 2 data for posoleucel in virus prevention in high-risk allo-HCT patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No end-organ viral disease observed in 23 high-risk allo-HCT patients receiving posoleucel.","Only 3 of 138 possible clinically significant infections occurred; 11 of 13 patients through Week 14 free of infection.","FDA agreed in principle to advance to Phase 3 registrational trial expected to start in 1H 2022.","Posoleucel targeting six viruses: AdV, BKV, CMV, EBV, HHV-6, and JCV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114157966.72900765,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-13T23:59:59+00:00|411891"}